An updated review on cancer risk associated with incretin mimetics and enhancers (Q38388920)

2 September 2017

1 reference

title

An updated review on cancer risk associated with incretin mimetics and enhancers (English)

1 reference

2 September 2017

Chin-Hsiao Tseng

1

1 reference

PubMed ID

25803196

2 September 2017

Kuo-Yang Lee

series ordinal

2

1 reference

PubMed ID

25803196

2 September 2017

Farn-Hsuan Tseng

series ordinal

3

1 reference

2 September 2017

1 January 2015

1 reference

Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews

2 September 2017

1 reference

2 September 2017

33

1 reference

2 September 2017

1

1 reference

2 September 2017

67-124

1 reference

Global estimates of the prevalence of diabetes for 2010 and 2030

2 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Epidemiological aspects of neoplasms in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and breast cancer in Taiwanese women: a detection bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Higher risk of mortality from lung cancer in Taiwanese people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and gastric cancer: the potential links

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Phototoxicity of herbal plants and herbal products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Epidemiology of primary liver cancer in Serbia and possible connection with cyanobacterial blooms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Polychlorinated biphenyls and cancer: an epidemiological assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Environmental toxicants--induced epigenetic alterations and their reversers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Guidelines for asbestos remediation at Italian superfund sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Nutritional chemoprevention of urinary tract tumors (UTT) induced by lithogenic agents: risk for UTT in children exposed to melamine-contaminated milk formulas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Thyroid disrupting chemicals in plastic additives and thyroid health

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A review on thiazolidinediones and bladder cancer in human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretins and thiazolidinediones in glucose homeostasis and cancer: role of common polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pdx1 and other factors that regulate pancreatic beta-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

COUP-TFII controls mouse pancreatic β-cell mass through GLP-1-β-catenin signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Dipeptidyl peptidase-4: a key player in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon like peptide-1 receptor expression in the human thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Old and new peptide receptor targets in cancer: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The efficacy and safety of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Do incretin-based therapies cause acute pancreatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Upregulation of rat Ccnd1 gene by exendin-4 in pancreatic beta cell line INS-1: interaction of early growth response-1 with cis-regulatory element

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin therapy and islet pathology: a time for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Do GLP-1-based therapies increase cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and thyroid cancer mortality: a 12-year prospective follow-up of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Thyroid cancer risk is not increased in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Diabetes and thyroid cancer risk: literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Increased levels of serum glucose-dependent insulinotropic polypeptide as a novel risk factor for human colorectal adenoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Why diabetes patients are more prone to the development of colon cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Allergy and risk of hematologic malignancies: associations and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1-based therapy for diabetes: what you do not know can hurt you.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1-based therapies: the dilemma of uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Genetic susceptible locus in NOTCH2 interacts with arsenic in drinking water on risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP1 and cancer: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Current thyroid cancer trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla-La Mancha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

GLP-1R agonist therapy for diabetes: benefits and potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretins and risk of neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pancreatitis associated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Potential applications for biguanides in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Proposed algorithm for management of patients with thyroid nodules/focal lesions, based on ultrasound (US) and fine-needle aspiration biopsy (FNAB); our own experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10590501.2015.1003496

10.1080/10590501.2015.1003496

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25803196